PSMA靶向放射性药物偶联物市场（按放射性核种类型、适应症、治疗类型、患者年龄层、最终用户和分销管道划分），全球预测，2026-2032年

2025 年，标靶 PSMA 放射性核种药物偶联物市场价值为 9.3575 亿美元，预计到 2026 年将成长至 10.3407 亿美元，到 2032 年将达到 20.2025 亿美元，复合年增长率为 11.62%。

关键市场统计数据
基准年 2025	9.3575亿美元
预计年份：2026年	1,034,070,000 美元
预测年份 2032	2,020,250,000 美元
复合年增长率 (%)	11.62%

将PSMA靶向放射性核素偶联物（PSMA-RNCs）的兴起定位为临床和商业性的转折点，需要综合运用科学和市场观点。

前列腺特异性膜抗原 (PSMA) 靶向放射性核素药物偶联物代表了分子标靶技术和放射性药物科学的融合，正在重塑前列腺肿瘤的治疗和诊断方法。近期临床进展已证实 PSMA 是放射性核种递送的高价值靶点，可实现恶性组织的成像和治疗性切除，从而实现更精准的患者筛选和个体化治疗。因此，药物研发人员、影像专家、临床试验团队和支付方正在重新审视其产品组合和临床路径，以将治疗性诊断策略整合到标准治疗方案中。

科学突破、监管调整和生产创新将如何共同重塑PSMA放射性核素疗法的临床开发和医疗服务？

在科学进步、监管变革和治疗路径重组的推动下，PSMA标靶放射性核治疗领域正经历着变革性的转变。 α发射同位素因其高线性能量传递率和克服抗药性机制的潜力而备受关注，而β发射同位素则因其安全性和有效性已得到充分验证，从而支持其更广泛的临床应用。同时，影像学和治疗诊断技术的进步正在改善患者筛选和疗效监测，这些技术的结合推动临床试验设计转向适应性强、生物标记增强型方法。

评估美国累积关税变化对营运和策略的影响，以及对放射性药物供应链韧性的影响。

预计美国2025年的政策变化和关税调整为放射性药物供应链带来了新的商业性复杂性。进口组件、专用放射化学设备和前驱材料的关税可能会增加采购成本，挤压製造商的利润空间。这给采购决策、合约结构和价格谈判带来了压力。为此，许多相关人员正在重新评估其供应商组合，并寻求更多本地伙伴关係关係，以对冲关税相关的波动风险，并确保对时效性同位素的持续供应。

分析临床、治疗、分销和人口统计细分市场，以确定PSMA放射性核种产品的客製化开发和商业化路径

对PSMA放射性核种领域进行细分，对于优先进行临床开发和商业化至关重要。依放射性核种类型进行分析涵盖α和β发射体以及诊断同位素。具体而言，锕-225因其α发射体疗效而备受关注，镓-68用于PET成像和诊断，镏-177作为具有成熟临床记录的治疗性β发射体，锝-99m则适用于更易于应用的成像Technetium。每种放射性核素都具有独特的放射生物学特性、生产和物流要求以及监管方面的考量，这些都会影响候选药物的选择和临床定位。

临床开发、生产能力和报销策略的区域比较（美洲、欧洲、中东和非洲、亚太地区）

区域趋势正在塑造PSMA靶向放射性核素偶联物的临床开发生态系统和商业性准入策略，美洲、欧洲、中东和非洲以及亚太地区呈现出不同的营运和监管现状。在美洲，成熟的临床试验基础设施、完善的核子医学网络以及不断完善的放射性药物监管体系，营造了有利于快速临床转化和早期商业性化的环境，同时也加剧了对放射化学能力和专业人才的竞争。

分析公司策略，这些策略结合了平台差异化、生产控制和临床整合，以增强其在放射性药物领域的竞争优势。

PSMA放射性核种领域主要企业的发展趋势围绕着策略联盟、放射化学能力的垂直整合以及临床开发生态系统的建构。领先的开发商强调平台的多功能性，将候选药物与多种放射性核素结合，以优化治疗指数并支持治疗诊断（治疗诊断学）应用。将放射性药物开发商与迴旋加速器营运商、专科药房和学术临床中心联繫起来的合作模式正变得越来越普遍，以解决生产限制以及设施对复杂处理和给药的准备。

为高阶主管实现PSMA放射性核种疗法的供应弹性、监管合规性和临床应用，制定切实可行的策略支柱

产业领导者必须采取多管齐下的策略，将PSMA靶向放射性核种偶联物的科学潜力转化为持续的临床和商业性成功。首先，要减少对单一来源的依赖，并透过投资可与关键测试设施毗邻的灵活生产模式，来克服短寿命同位素固有的物流障碍。同时，也应建立关键前驱和设备的长期供应协议和冗余备份，从而降低贸易和地缘政治动盪带来的风险。

报告采用透明的调查方法，说明了专家访谈、技术文献综述和营运分析，这些都构成了报告结论和建议的基础。

本研究综合分析采用多方法论，结合了专家访谈、同行评审的临床研究和监管指南的文献综述，以及放射性药物和物流实践的营运分析。专家咨询对象包括核子医学和肿瘤内科的临床医生、具有放射性药物经验的监管事务专业人员、放射化学公司的生产和供应链经理，以及参与进行复杂临床试验的临床营运专业人员。这些访谈提供了关于临床决策、设施准备以及同位素处理操作限制的定性见解。

透过协作的方式整合临床、营运和商业性需求，从而实现PSMA放射性核素疗法的成功以及更广泛的临床整合。

累积分析表明，PSMA靶向放射性核素药物偶联物代表了前列腺癌治疗的模式转移，实现了精准干预，充分利用了影像和治疗的互补优势。放射性核种选择技术的进步，加上影像技术的改进和整合的临床路径，拓展了治疗的可能性，同时也带来了必须积极应对的生产、监管和报销方面的挑战。该领域的成功同样依赖临床疗效、营运可行性、供应链韧性以及整个医疗生态系统中相关人员之间的协作。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依放射性核种类型分類的PSMA标靶放射性药物偶联物市场

• 锕-225
• 镓-68
• 镏-177
• Technetium-99m

9. 依适应症分類的PSMA标靶放射性偶联物市场

• 转移性去势去势抗性前列腺癌
• 转移性去势敏感性前列腺癌
• 非转移性前列腺癌

第十章 PSMA靶向放射性药物偶联物市场（按治疗方法划分）

• 联合治疗
• 单药治疗

11. 依患者年龄层分類的PSMA标靶放射性偶联药物市场

• 成年人（18-65岁）
• 老年人（65岁以上）

第十二章 PSMA靶向放射性药物偶联物市场（按最终用户划分）

• 诊所
• 医院
• 诊断影像中心
• 研究所

13. PSMA靶向放射性偶联物市场（按分销管道划分）

• 直接购买
• 医院药房
• 专科药房

14. 按地区分類的PSMA标靶放射性偶联物市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章 PSMA靶向放射性偶联物市场（按组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

16. 各国PSMA标靶放射性偶联物市场

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

17. 美国PSMA标靶放射性偶联物市场

18. 中国PSMA标靶放射性药物偶联物市场

第十九章 竞争情势

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Actinium Pharmaceuticals, Inc.
• ACUITY Pharmaceuticals, Inc.
• Advanced Accelerator Applications
• Bayer AG
• Curium Pharma SA
• Endocyte Therapeutics GmbH
• GE Healthcare Limited
• Isoray Medical, Inc.
• ITM Isotope Technologies Munich SE
• Jubilant Life Sciences Limited
• Lantheus Holdings, Inc.
• Novartis AG
• Point Biopharma Global Inc.
• Point Biopharma Inc.
• PSMA Therapeutics LLC
• RadioMedix, Inc.
• Sorrento Therapeutics, Inc.
• Telix Pharmaceuticals Limited
• Telix Pharmaceuticals Pty Ltd
• Theragnostics, Inc.
• Viamet Pharmaceuticals, Inc.

The Targeted PSMA Radionuclide Drug Conjugates Market was valued at USD 935.75 million in 2025 and is projected to grow to USD 1,034.07 million in 2026, with a CAGR of 11.62%, reaching USD 2,020.25 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 935.75 million
Estimated Year [2026]	USD 1,034.07 million
Forecast Year [2032]	USD 2,020.25 million
CAGR (%)	11.62%

Framing the rise of PSMA-targeted radionuclide conjugates as a clinical and commercial inflection point that demands integrated scientific and market perspectives

Prostate-specific membrane antigen (PSMA) targeted radionuclide drug conjugates represent a convergence of molecular targeting and radiopharmaceutical science that is reshaping therapeutic and diagnostic approaches in prostate oncology. Recent clinical progress has validated PSMA as a high-value target for delivering radionuclides that can both image and therapeutically ablate malignant tissue, thereby enabling more precise patient selection and treatment personalization. As a result, drug developers, imaging specialists, clinical trial teams, and healthcare payers are reassessing portfolios and clinical pathways to integrate theranostic strategies into standard of care.

This report synthesizes cross-disciplinary evidence and stakeholder perspectives to present a cohesive understanding of the technical, clinical, and commercial dynamics influencing PSMA-targeted radionuclide drug conjugates. It examines radionuclide selection criteria, clinical indication differentiation, therapeutic modalities, delivery and administration imperatives, and end-user workflows. By grounding the discussion in operational realities-such as manufacturing complexity, regulatory pathways, and logistics-it aims to equip decision-makers with the context necessary to prioritize investments, design robust clinical programs, and align market access strategies with evolving standards of care.

Through an evidence-focused lens, the introduction sets the stage for deeper analysis by highlighting how advances in alpha and beta emitters, improvements in imaging diagnostics, and evolving care models are collectively expanding the therapeutic potential of PSMA-targeted conjugates while creating new operational and commercial challenges that stakeholders must address.

How scientific breakthroughs, regulatory adaptation, and manufacturing innovation are collectively reconfiguring clinical development and care delivery for PSMA radionuclide therapeutics

The landscape of PSMA-targeted radionuclide therapeutics is undergoing transformative shifts driven by scientific advances, regulatory evolution, and care pathway reconfiguration. Alpha-emitting isotopes have gained prominence for their high linear energy transfer and potential to overcome resistance mechanisms, while beta emitters continue to provide well-characterized safety and efficacy profiles that support broader clinical adoption. Concurrently, improved imaging agents and theranostic pairing enhance patient selection and response monitoring, which together shift clinical trial design toward adaptive and biomarker-enriched approaches.

Moreover, regulatory frameworks are adapting to the unique nature of radiopharmaceuticals, with agencies showing greater willingness to consider composite endpoints and imaging-based selection criteria that can accelerate evidence generation. Payer landscapes are likewise evolving, albeit more conservatively, as real-world evidence and health economic modeling begin to demonstrate value beyond traditional survival endpoints. In parallel, manufacturing paradigms are transitioning to accommodate demand for short-lived isotopes through regionalized production hubs, modular radiochemistry platforms, and closer integration with clinical sites to minimize decay loss and logistical inefficiency.

These converging shifts are prompting sponsors to re-evaluate trial geography, partner ecosystems, and commercialization tactics. Strategic alliances between academic centers, radiochemistry innovators, and specialty pharmacies are becoming a practical necessity rather than an optional enhancement. As a result, the industry is moving from isolated proof-of-concept activities to coordinated, scalable programs that balance clinical rigor with operational feasibility, which ultimately catalyzes broader access and integration of PSMA radionuclide therapeutics into multidisciplinary oncology care.

Evaluating the operational and strategic repercussions of cumulative tariff shifts in the United States and their implications for radiopharmaceutical supply chain resilience

Anticipated policy changes and tariff adjustments in the United States in 2025 have introduced a new dimension of commercial complexity for radiopharmaceutical supply chains. Tariff measures on imported components, specialized radiochemistry equipment, or precursor materials can elevate procurement costs and compress manufacturer margins, which in turn pressures decisions around sourcing, contract structures, and pricing negotiations. In response, many stakeholders are reassessing supplier portfolios and exploring nearer-shore partnerships to hedge against tariff-related volatility and to secure continuity for time-sensitive isotopes.

Beyond direct cost implications, cumulative tariff effects propagate through logistical networks that are already constrained by the decay characteristics of radionuclides and the need for tightly controlled cold chain and regulatory-compliant transport. This layering of trade policy over operational constraints emphasizes the strategic value of distributed manufacturing models and local radiopharmacy capacity that reduce cross-border movement of critical materials. Consequently, sponsors and service providers are realigning capital expenditure plans and prioritizing investments that increase domestic resilience, whether that means co-locating radiochemistry nodes with clinical trial sites or establishing long-term supply agreements with regional cyclotron operators.

At the same time, tariff-driven pressures are incentivizing more creative contracting between developers and payers, including value-based arrangements and outcomes-linked reimbursement that can mitigate short-term cost increases. Importantly, these dynamics are also accelerating collaborative advocacy efforts to clarify regulatory expectations and to secure exemptions or mitigations for clinically essential materials. Taken together, the cumulative effect of tariff changes is catalyzing structural adaptation across the ecosystem, prompting a rebalancing of cost, access, and operational risk in the delivery of PSMA-targeted radionuclide therapies.

Dissecting clinical, therapeutic, distributional, and demographic segments to reveal tailored development and commercial pathways for PSMA radionuclide products

A granular understanding of segmentation is critical for prioritizing clinical development and commercialization pathways in the PSMA radionuclide space. Analysis by radionuclide type spans alpha and beta emitters and diagnostic isotopes, specifically Actinium-225 for alpha-emitter potency, Gallium-68 for PET imaging and diagnostics, Lutetium-177 for therapeutic beta emissions with established clinical precedent, and Technetium-99m for accessible imaging applications. Each radionuclide brings distinct radiobiological profiles, production and logistics requirements, and regulatory considerations that influence candidate selection and clinical positioning.

Indication-specific segmentation covers metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and non-metastatic prostate cancer. These indications differ in clinical endpoint expectations, treatment sequencing, and patient heterogeneity, which affects trial design and evidence generation strategies. Therapeutic modality-whether pursued as combination therapy with established systemic agents or as monotherapy-dictates safety evaluation priorities and combination toxicity management, while also shaping value propositions for clinicians and payers.

End-user segmentation identifies clinical settings such as clinics, hospitals, imaging centers, and research institutes where administration and operational workflows vary significantly. Distribution channel considerations, including direct purchase, hospital pharmacy provisioning, and specialty pharmacy networks, determine procurement pathways and influence reimbursement negotiation. Administration route segmentation, centered on intravenous injection, underscores the procedural requirements and staff competencies necessary for safe delivery. Patient age group segmentation differentiates adult populations aged 18 to 65 from senior cohorts aged 65 and above, reflecting divergent comorbidity profiles and tolerance considerations that must be integrated into clinical development and marketing strategies.

Comparative regional considerations for clinical development, manufacturing capacity, and reimbursement strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape both clinical development ecosystems and commercial access strategies for PSMA-targeted radionuclide conjugates, with the Americas, Europe Middle East & Africa, and Asia-Pacific each presenting distinct operational and regulatory realities. In the Americas, mature clinical trial infrastructure, established nuclear medicine networks, and progressive regulatory engagement for radiopharmaceuticals create an environment conducive to rapid clinical translation and early commercial entry, while also intensifying competition for radiochemistry capacity and trained personnel.

The Europe, Middle East & Africa region offers heterogeneous regulatory pathways and reimbursement systems that require nuanced market entry approaches. In many European countries, strong academic collaborations and centralized radiopharmacy capabilities facilitate multicenter trials and theranostic program development, but divergent reimbursement frameworks necessitate tailored health economic narratives and country-specific access strategies. Meanwhile, emerging centers in the Middle East and Africa are investing in nuclear medicine capacity, presenting opportunities for capacity-building partnerships and phased market development.

Asia-Pacific encompasses a wide spectrum from highly developed healthcare systems with robust regulatory infrastructure to rapidly expanding markets that prioritize capacity expansion. Regional differences in isotope production capabilities, imaging infrastructure, and clinical practice patterns influence site selection for trials and commercial rollouts. Consequently, a segmented regional strategy that aligns clinical evidence generation with local production capabilities and payer expectations is essential for effective deployment across these territories.

Analyzing corporate strategies that combine platform differentiation, manufacturing control, and clinical integration to strengthen competitive advantage in radiopharmaceuticals

Key company-level dynamics in the PSMA radionuclide arena revolve around strategic partnerships, vertical integration of radiochemistry capabilities, and the orchestration of clinical-development ecosystems. Leading developers emphasize platform versatility, enabling candidates to be paired with multiple radionuclides to optimize therapeutic indices and to support theranostic use. Collaborative models that link radiopharmaceutical developers with cyclotron operators, specialty pharmacies, and academic clinical sites are increasingly prevalent because they address both production constraints and site readiness for complex handling and administration.

At the corporate level, differentiation often emerges through intellectual property around targeting moieties, linker chemistry, and radiolabeling processes, as well as through proprietary manufacturing workflows that improve yield and reduce decay losses. Companies that invest in modular manufacturing technologies and in-house radiochemistry expertise tend to achieve greater control over supply continuity and quality assurance. Additionally, firms that proactively engage with regulatory bodies, payer stakeholders, and multidisciplinary clinical consortia are more effective at aligning clinical programs with real-world evidence requirements and access pathways.

Competitive positioning also depends on the ability to demonstrate physician adoption and to embed therapies into established care pathways. Organizations that support site training, offer turnkey logistics solutions, and design pragmatic clinical programs that respect operational constraints gain traction more quickly. In sum, the most resilient companies are those that integrate scientific differentiation with operational execution and stakeholder alignment across the development-to-delivery continuum.

Actionable strategic pillars for senior executives to secure supply resilience, regulatory alignment, and clinical adoption for PSMA radionuclide therapies

Industry leaders must adopt a multipronged strategy to convert scientific promise into durable clinical and commercial outcomes for PSMA-targeted radionuclide conjugates. First, investing in flexible production models that reduce dependence on single-source supply and that can be co-located with key trial sites will mitigate logistical barriers intrinsic to short-lived isotopes. Coupled with this, establishing long-term supplier agreements and redundancy for critical precursors and equipment reduces exposure to trade-related and geopolitical disruptions.

Second, forging early and transparent engagement with regulators and payers helps shape feasible evidence generation plans that balance accelerated access with comprehensive safety and value demonstration. Strategic clinical designs that incorporate robust imaging-based selection criteria, relevant patient-reported outcomes, and pragmatic endpoints can expedite adoption while addressing payer concerns. Third, building integrated commercial models that include specialist training, logistics support, and clear clinical pathways for administration will facilitate uptake among hospitals, clinics, and imaging centers. Finally, partnering with research institutions and specialty pharmacies to create end-to-end service offerings enhances site readiness and ensures that operational workflows align with therapeutic protocols, thereby accelerating real-world implementation.

Methodological transparency describing expert interviews, technical literature synthesis, and operational analysis underpinning the report's findings and recommendations

This research synthesis is informed by a multi-method approach that integrates primary interviews with subject-matter experts, secondary literature review of peer-reviewed clinical studies and regulatory guidance, and operational analysis of radiopharmacy and logistics practices. Expert consultations included clinicians specializing in nuclear medicine and medical oncology, regulatory affairs professionals with radiopharmaceutical experience, manufacturing and supply chain leads from radiochemistry enterprises, and clinical operations specialists involved in complex trial execution. These engagements provided qualitative insights into clinical decision-making, site readiness, and the operational constraints of isotope handling.

Secondary evidence was drawn from recent clinical trial publications, regulatory approvals and guidance documents, and publicly available technical literature on radionuclide production and radiochemistry methodologies. Operational analysis focused on production workflows for Actinium-225, Gallium-68, Lutetium-177, and Technetium-99m, the logistical implications of half-life and decay, and the infrastructure requirements of hospitals, clinics, and specialty pharmacies. Throughout the methodology, triangulation was applied to reconcile divergent perspectives and to ensure the report's findings are grounded in corroborated evidence and practical operational realities.

Synthesis of clinical, operational, and commercial imperatives that define success for PSMA radionuclide therapeutics and the collaborative path to broader clinical integration

The cumulative analysis underscores that PSMA-targeted radionuclide drug conjugates represent a paradigm shift in prostate cancer care that harnesses the complementarity of imaging and therapy to enable precision interventions. Technological advances in radionuclide selection, coupled with improved imaging and clinical pathway integration, are expanding therapeutic possibilities while bringing to the fore manufacturing, regulatory, and reimbursement challenges that must be managed proactively. Success in this space depends not only on clinical efficacy but equally on operational execution, supply chain resilience, and stakeholder alignment across healthcare ecosystems.

Looking forward, organizations that prioritize adaptable production models, design evidence strategies that satisfy both regulators and payers, and invest in comprehensive site support programs will be best positioned to convert clinical promise into routine clinical practice. The intersection of radiochemistry innovation, pragmatic clinical trial design, and purposeful commercial planning creates an opportunity to deliver meaningful patient benefit while establishing sustainable business models for a new generation of theranostic agents. Ultimately, achieving widespread clinical integration will require coordinated efforts across industry, academia, clinical networks, and policy stakeholders to align incentives and to scale responsible access.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted PSMA Radionuclide Drug Conjugates Market, by Radionuclide Type

• 8.1. Actinium-225
• 8.2. Gallium-68
• 8.3. Lutetium-177
• 8.4. Technetium-99m

9. Targeted PSMA Radionuclide Drug Conjugates Market, by Indication

• 9.1. Metastatic Castration-Resistant Prostate Cancer
• 9.2. Metastatic Castration-Sensitive Prostate Cancer
• 9.3. Non-Metastatic Prostate Cancer

10. Targeted PSMA Radionuclide Drug Conjugates Market, by Therapy Type

• 10.1. Combination Therapy
• 10.2. Monotherapy

11. Targeted PSMA Radionuclide Drug Conjugates Market, by Patient Age Group

• 11.1. Adult 18-65
• 11.2. Senior 65+

12. Targeted PSMA Radionuclide Drug Conjugates Market, by End User

• 12.1. Clinic
• 12.2. Hospital
• 12.3. Imaging Center
• 12.4. Research Institute

13. Targeted PSMA Radionuclide Drug Conjugates Market, by Distribution Channel

• 13.1. Direct Purchase
• 13.2. Hospital Pharmacy
• 13.3. Specialty Pharmacy

14. Targeted PSMA Radionuclide Drug Conjugates Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Targeted PSMA Radionuclide Drug Conjugates Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Targeted PSMA Radionuclide Drug Conjugates Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Targeted PSMA Radionuclide Drug Conjugates Market

18. China Targeted PSMA Radionuclide Drug Conjugates Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. Actinium Pharmaceuticals, Inc.
• 19.6. ACUITY Pharmaceuticals, Inc.
• 19.7. Advanced Accelerator Applications
• 19.8. Bayer AG
• 19.9. Curium Pharma S.A.
• 19.10. Endocyte Therapeutics GmbH
• 19.11. GE Healthcare Limited
• 19.12. Isoray Medical, Inc.
• 19.13. ITM Isotope Technologies Munich SE
• 19.14. Jubilant Life Sciences Limited
• 19.15. Lantheus Holdings, Inc.
• 19.16. Novartis AG
• 19.17. Point Biopharma Global Inc.
• 19.18. Point Biopharma Inc.
• 19.19. PSMA Therapeutics LLC
• 19.20. RadioMedix, Inc.
• 19.21. Sorrento Therapeutics, Inc.
• 19.22. Telix Pharmaceuticals Limited
• 19.23. Telix Pharmaceuticals Pty Ltd
• 19.24. Theragnostics, Inc.
• 19.25. Viamet Pharmaceuticals, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 13. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 14. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ACTINIUM-225, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ACTINIUM-225, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ACTINIUM-225, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GALLIUM-68, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY NON-METASTATIC PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY NON-METASTATIC PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY NON-METASTATIC PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADULT 18-65, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADULT 18-65, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADULT 18-65, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SENIOR 65+, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SENIOR 65+, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SENIOR 65+, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY IMAGING CENTER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY IMAGING CENTER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY IMAGING CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 63. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 64. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 65. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 66. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 67. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 68. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 69. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 70. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 71. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 72. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 73. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 74. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 75. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 76. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 77. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 78. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 79. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 80. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 81. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 82. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 83. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 91. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 92. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 93. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 94. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 95. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 96. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 97. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 98. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 100. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 101. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 102. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 103. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 104. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 105. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 107. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 108. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 109. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 110. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 111. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 112. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 113. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 114. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 115. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 116. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 117. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 118. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 119. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 120. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 121. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 122. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 123. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 124. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 125. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 126. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 127. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 128. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 129. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 130. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 131. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 132. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 133. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 134. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 135. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 136. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 137. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 138. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 139. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 140. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 141. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 142. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 143. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 144. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 145. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 146. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 147. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 148. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 149. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 150. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 151. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 152. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 153. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 154. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 155. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 156. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 157. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 158. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 159. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 160. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 161. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 162. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 163. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 164. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 165. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 166. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 167. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 168. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 169. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 170. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 171. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
• TABLE 172. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 173. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
• TABLE 174. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 175. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 176. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)